Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company’s laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
企業コードFLGT
会社名Fulgent Genetics Inc
上場日Sep 28, 2016
最高経営責任者「CEO」Mr. Ming Hsieh
従業員数1313
証券種類Ordinary Share
決算期末Sep 28
本社所在地4399 Santa Anita Ave
都市EL MONTE
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号91731
電話番号16263500537
ウェブサイトhttps://www.fulgentgenetics.com/
企業コードFLGT
上場日Sep 28, 2016
最高経営責任者「CEO」Mr. Ming Hsieh
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし